Figure 1. Roya Lisboa, RN, holding a SorbaView bandage (Centurion Medical Products).
Small innovations can make a big difference. It’s a recurrent theme in interventional cardiology. Small changes or new application of a common piece or equipment, supply, or method can make a difference in your lab.1,2
Figure 2. The Tegederm bandage being applied to the radial sheath. Lower right, view of draping for our radial procedures using the Armen glove method.3
Last week, Roya Lisboa (Figure 1), one of our super cath lab nurses, handed me an IV bandage to secure the radial sheath. I’d been complaining, as many of my colleagues have reported, that the usual Tegederm clear plastic bandage (Figure 2) with a slit, holds the sheath in place for most routine cases but fails for longer procedures, especially when blood gets under the plastic.
Figure 3. The SorbaView bandage. Left, adhesive side before removal of paper covers; middle, front side of SorbaView bandage; right, different size SorbaView bandage showing clear window and a port to see hub of catheter/sheath/IV. Blue lines are reinforcing tapes incorporated into bandage.
The SorbaView bandage (Centurion Medical Products) (Figure 3) has a clear window and fabric adhesive border with a locking piece of adhesive added after the bandage is placed. It is usually used to protect IV needles and catheters. The fabric border prevents blood from leaking into the puncture area. To secure the radial sheath, we made sure to attach the fabric adhesive to the hub of the sheath with the side arm passing under the adhesive and the locking patch over the side arm (Figure 4).
Figure 4A. Application of the SorbaView bandage to the radial sheath. The fabric tape is adhered to the sheath hub. The side arm is looped to the top of the arm and covered by the SorbaView clear window and fabric border.
I asked my expert colleagues what they used for securing their radial sheaths and the answers were interesting:
Most respondents used Tegederm, but complained that its securing function is short-lived and if blood gets under it, it is a mess and stops working. This usually occurs involving a long case with multiple catheter exchanges.
Figure 4B. Final SorbaView application with locking patch holding the side arm as it exits the sheath. The bandage stayed dry for the entire procedure and was easy to remove.
Several operators use long sheaths with no securing technique needed.
Several operators use a suture if the sheath needs to be secured for long case.
One European operator doesn’t use sheaths and goes sheathless for his procedures.
Figure 5. Three sheath-securing devices. Left, Statlock (Maquet); top right, StayFIX (Merit Medical); bottom right, StatLock arterial ultra-stabilization device (Bard Access Systems).
Several other devices available in our lab were investigated but none seemed suitable (Figure 5). While only a small change in our radial technique, the use of a new securing method may be a big advance for the procedure. It’s always a good idea to keep your eyes open in the cath lab.
References
Kern MJ. New ideas from cardiac cath lab staff. Cath Lab Digest. 2008 Mar; 16(4). Available online at https://www.cathlabdigest.com/articles/New-Ideas-Cardiac-Cath-Lab-Staff. Accessed Dec 12, 2017.
Kern MJ. Small innovations can make a big difference: the role of staff initiatives to drive efficiency in the cath lab. Cath Lab Digest. 2017 Feb; 25(2). Available online at https://www.cathlabdigest.com/article/Small-Innovations-Can-Make-Big-Difference-Role-Staff-Initiatives-Drive-Efficiency-Cath-Lab. Accessed December 12, 2017.
Kern MJ. The Armen glove for radial access prep — a better way. Cath Lab Digest. 2010 May; 18(5). Available online at https://www.cathlabdigest.com/articles/The-Armen-Glove-Radial-Access-Prep-%E2%80%93-A-Better-Way. Accessed December 12, 2017.
The 563-patient blinded study found that HearO predicted more than 70% of heart failure events at an average of 24.6 days before they occurred, with high patient compliance and no device-related adverse events.
The 563-patient blinded study found that HearO predicted more than 70% of heart failure events at an average of 24.6 days before they occurred, with high patient compliance and no device-related adverse events.
Amgen announced results from a large real-world study showing that treatment with Repatha® (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared with ezetimibe in people with atherosclerotic cardiovascular disease...
Amgen announced results from a large real-world study showing that treatment with Repatha® (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared with ezetimibe in people with atherosclerotic cardiovascular disease...
Compared with usual care based on stress testing, care guided by AI-based quantitative coronary CT analysis (AI-QCT) improved diagnostic certainty and led to more patients receiving lipid-lowering therapy.
Compared with usual care based on stress testing, care guided by AI-based quantitative coronary CT analysis (AI-QCT) improved diagnostic certainty and led to more patients receiving lipid-lowering therapy.
Patients with acute myocardial infarction complicated by cardiogenic shock who received intravenous cangrelor had less microvascular obstruction and greater recovery of left ventricular function than those receiving crushed oral ticagrelor,...
Patients with acute myocardial infarction complicated by cardiogenic shock who received intravenous cangrelor had less microvascular obstruction and greater recovery of left ventricular function than those receiving crushed oral ticagrelor,...
Sub-analysis presented at TCT 2026 shows substantial clot burden reduction and improved right-heart function with the Symphony Thrombectomy System despite greater baseline cardiac stress in women
Sub-analysis presented at TCT 2026 shows substantial clot burden reduction and improved right-heart function with the Symphony Thrombectomy System despite greater baseline cardiac stress in women
Nearly nine out of 10 patients experienced a clinical benefit at six months. Medtronic receives FDA approval for U.S. labeling update to Symplicity blood pressure procedure, expanding clinical evidence informing treatment options
Nearly nine out of 10 patients experienced a clinical benefit at six months. Medtronic receives FDA approval for U.S. labeling update to Symplicity blood pressure procedure, expanding clinical evidence informing treatment options
Annual TAVR procedures among patients younger than 70 rose from 15 in 2014 to 134 in 2024 within one health system, driven primarily by patients in their 60s, while surgery remained predominant.
Annual TAVR procedures among patients younger than 70 rose from 15 in 2014 to 134 in 2024 within one health system, driven primarily by patients in their 60s, while surgery remained predominant.
